First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery

First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
The pharmaceutical development company NanOlogy has enrolled the first participant in its Phase 2 trial evaluating the safety and effectiveness of NanoPac, a new delivery method for the anti-cancer treatment paclitaxel in ovarian cancer patients. “If successful, we may add to the newer treatment options that are just becoming available and ideally improve the prognosis

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *